| Year | Ceftriaxone | Azithromycin | Cefixime | Ciprofloxacin | Spectinomycin | Gentamicin | β-lactamase |
|---|
| 2006 | 87.6–100 | 95.3–100 | – | 49.5–99.1 | – | – | 96.3–100 |
| 2007 | 95.3–100 | 75.6–100 | – | 90.3–100 | – | – | 100 |
| 2008 | 93.8–100 | 41.7–100 | – | 94.2–100 | 100 | – | 98–100 |
| 2009 | 95.8–100 | 87–100 | 100 | 92.9–100 | 100 | 100 | 97.5–100 |
| 2010 | 93.8–100 | 89.1–100 | 97.1–100 | 92.6–100 | 100 | 100 | 98.2–100 |
| 2012 | 95.8–100 | 75a – 100 | 95.8–100 | 80b - 100 | 100 | 98.1–100 | 97.9–98.1 |
| 2013 | 95.4–100 | 89a - 100 | 95.5–100 | 80b - 100 | 100 | 97.3–100 | 99.1–100 |
- The table contains data from; Austria (2012–2013, all antimicrobials); Belgium (2006–2009, no gentamicin or cefixime data); Cyprus (2012–2013, no spectinomycin, gentamicin or β-lactamase data); Denmark (2006–2009, ceftriaxone, ciprofloxacin and β-lactamase data only); France (2008–2010, no azithromycin or gentamicin data); Greece (2007–2010, no gentamicin data); Iceland (2012–2013, no spectinomycin, gentamicin or β-lactamase data); Ireland (2012, ceftriaxone, azithromycin and cefixime data only); Italy (2007, azithromycin and ciprofloxacin only, 2010–2011 all antimicrobials); Malta (2012–2013, no gentamicin or β-lactamase data); Norway (2012–2013, no β-lactamase data); Portugal (2009–2010, no azithromycin data); Slovenia (2011–2013, all antimicrobials); Spain (2006–2009, no cefixime or gentamicin data); Sweden (2006–2009, no cefixime or gentamicin data); The Netherlands (2006–2010, ceftriaxone, ciprofloxacin and β-lactamase data only) and the UK (2006–2010, no gentamicin data). Data from Slovenia was only available for 2011 so data is not shown, however all concordances for 2011 were within specified limits
- aAll discrepant isolates on the resistance breakpoint
- bOnly a very low number of isolates available for comparison from two labs, so 1–2 mismatches resulted in only 80% concordance, however overall concordance of the resistance category comparisons was ≥97%
